Salute e Benessere

IBA opens the world of science and technology to secondary school girls

Its Innovat’her event brought together female students to explore careers in STEMLouvain-la-Neuve, Belgium, October 17, 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, hosted theInnovat’herevent yesterday, aimed at girls in their fifth and sixth years of secondary school. The goal was to introduce them to scientific and technical careers, which remain underrepresented in the academic choices of female students.The event...
Nasdaq GlobeNewswire
17/10/2025

Dietary Fiber Gummies Market to Reach USD 13.44 billion by 2032, Growing At An…

The dietary fiber gummies market is experiencing remarkable growth, driven by increasing health consciousness, rising digestive health concerns, and consumer preference for convenient supplement formats. According to Credence Research "The dietary fiber gummies market was valued at USD 5.75 billion in 2024 and is anticipated to reach USD 13.44 billion by 2032, at a CAGR of 11.2% during the forecast period." This exceptional expansion reflects the growing recognition of fiber's…
PR Newswire
17/10/2025

Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3…

/3 clinical study comparing the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), to nivolumab for the neoadjuvant treatment of patients with stage Ⅱ/Ⅲ, resectable, actionable genomic aberration (AGA)-negative, non-small cell lung cancer (“NSCLC”) has been approved by the U.S. Food and Drug Administration (the “FDA”).Lung cancer is currently a malignant tumor with the highest prevalence and mortality rate in the world. According to GLOBOCAN, there...
Nasdaq GlobeNewswire
17/10/2025

Indolent Lymphoma Market Experiences Significant Growth Amid Evolving…

Indolent Lymphoma Market Summary Indolent Lymphoma Market Summary Discover the indolent lymphoma new treatment @New Treatments for Indolent Lymphoma Key Factors Driving the Growth of the Indolent Lymphoma Market Advancements in Targeted and Immunotherapy Treatments The development of novel therapies, including oral and injectable medications, has improved the management of indolent lymphoma. These treatments offer greater efficacy, reduced side effects, and more precise...
PR Newswire
16/10/2025

Galapagos Announces Appointment of Fred Blakeslee as General Counsel

Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025 . Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period.“We are very pleased to welcome Fred to the executive team,” said Henry Gosebruch, CEO of Galapagos. “He brings a unique combination of top-tier legal expertise,...
Nasdaq GlobeNewswire
16/10/2025

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet…

○ Efficacy:ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status○ In the target Phase 2 population,...
Nasdaq GlobeNewswire
16/10/2025

AB Science provides intitial Phase 1 data for the combination of AB8939 with…

PRESS RELEASEAB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIAParis, 16 October 2025, 9pm CETAB Science SA(Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML).The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ ...
Nasdaq GlobeNewswire
16/10/2025

Proya Cosmetics Shares Its Vision for the Future of Beauty at Cosmetic 360…

"I am honored to share our company's journey, our commitment, and our investments in contributing to the future of cosmetics on a global scale," said Mr. Juncheng HOU, Founder and Chairman of Proya Cosmetics. "Innovation is central to our approach, and Cosmetic 360 is a valuable opportunity for us to introduce ourselves and exchange with the international community. This year's theme, 'Predictions,' aligns well with our goal of anticipating the creation of tomorrow's cosmetics and…
PR Newswire
16/10/2025

EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter…

Revenue up 11.7% in the third quarterBest quarterly performance ever for the GroupGroup’s revenue +11.7% in the third quarter at constant exchange rates 1, +8.8% in the nine monthsWearables major boost, enlarging the portfolio with a strong pipeline of product innovationVision care and sunglasses growing 5% at constant exchange rates 1and perimeterNorth America and EMEA up double digits in both PS and DTC channelsStellest supported by strong clinical results,...
Nasdaq GlobeNewswire
16/10/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – October 16, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on October 15, 2025, from Atlas Special Opportunities II…
Actusnews Wire
16/10/2025

Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A…

NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 16 October 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM…
Nasdaq GlobeNewswire
16/10/2025

Hagar hf: Financial results for Q2 2025/26

Strong performance and a new retail center in the Faroe Islands The interim financial statements of Hagar hf. for the second quarter of the 2025/26 financial year were approved by the company’s Board of Directors and CEO at a board meeting held on 16 October 2025. The statements cover the period from 1 March to 31 August 2025. The interim financial statements include the consolidated accounts of the company and its subsidiaries and have been prepared in accordance with International...
Nasdaq GlobeNewswire
16/10/2025

VIRBAC Announces Third Quarter 2025 Sales

Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scopeUpgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and scopeAdjusted recurring operating income¹ expected around 16% Press release on October 16, 2025, after market close at 5:45 p.m. CESTKEY FIGURESRevenue in first half of 2025 €1102.4MGrowth at constant exchange ratesand scope 2...
Nasdaq GlobeNewswire
16/10/2025

Wingderm®'s Mesoskin Marks New Milestone in Non-Invasive Delivery with 1.1…

Prof. Hang Wang, Executive Chairman of AMWC China, observed the use of Mesoskin in professional settings. She noted that Mesoskin assists with the application of high-molecular-weight cosmetic ingredients in a gradual and controlled manner. Unlike directly applying products or using tools such as a derma pen, Mesoskin's cartridge tip is designed to cover a larger area, helping beauticians apply cosmetic products efficiently while maintaining a comfortable experience. With its non-invasive design…
PR Newswire
16/10/2025

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy…

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDMTM. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples…
PR Newswire
16/10/2025

Natural Dyes Market to Reach $2.6 Billion, Globally, by 2034 at 6% CAGR: Allied…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A325663 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A325663 Prime determinants of growth The natural dyes market is experiencing robust growth, driven by increasing consumer demand for eco-friendly and sustainable products. Heightened awareness of the environmental and health hazards associated with synthetic dyes—such as water...
PR Newswire
16/10/2025

Infection Control Market worth $77.67 billion by 2030 with 6.3% CAGR |…

Browse in-depth TOC on "Infection Control Market" Browse in-depth TOC on "Infection Control Market" 635 - Tables59 - Figures616 - Pages By treatment,the infection control market is divided into five main segments based on treatment: sterilization products & services, cleaning & disinfection products, protective barriers, endoscope reprocessing products, and other infection control products. Cleaning and disinfection products are crucial in infection control as...
PR Newswire
16/10/2025

Hormonal Contraceptive Market to Reach $26.6 billion, Globally, by 2035 at 3.6%…

Request Sample of the Report on Global Hormonal Contraceptive Market 2035 - https://www.alliedmarketresearch.com/request-sample/4574 Request Sample of the Report on Global Hormonal Contraceptive Market 2035 -https://www.alliedmarketresearch.com/request-sample/4574 Prime determinants of growth The growth of the hormonal contraceptives market is driven by rise in prevalence of unintended pregnancies, increase in awareness of family planning, and government initiatives promoting...
PR Newswire
16/10/2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE…

To that end, Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD, have been invited as collaborating authors for a "Critical Perspectives" article on lacrimal occlusion in the setting of cataract and refractive surgery, which will appear in an upcoming issue of Expert Review of Ophthalmology. Lead author Vance Thompson notes that "Dry eye disease can influence preoperative planning, surgical outcomes, postoperative recovery, satisfaction, and quality of life in patients…
PR Newswire
16/10/2025

OpenEvidence and Veeva Announce Open Vista Partnership

"We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences," said Veeva CEO Peter Gassner. "Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them. With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical…
PR Newswire
16/10/2025

Seminal new study on the role of circulating tumour-cell clusters in end-of-life…

Detailed work by Prof. Aceto and others over the past decade has shown that CTC clusters have a much higher propensity to form metastases compared to single CTCs. Building on this, the present study published in Nature Medicine (link) is groundbreaking in uncovering a link between the increased number and size of CTC clusters and vascular occlusions, strongly suggestive of vascular failure as a cause of death in cancer patients. Detailed work by Prof. Aceto and others over the past decade has...
PR Newswire
16/10/2025

Genomics launches Mystra: the world's first and original AI-enabled human…

The pharmaceutical industry faces a significant research and development (R&D) productivity crisis, with the failure rate for drug candidates in clinical trials soaring to 95%. This rate pushes the average cost of bringing a new medicine to market beyond $2.3 billion, leading to unsustainable pricing and restricted patient access to life-saving treatments. Genomics is addressing this challenge by equipping researchers with a powerful solution built on the fact that targets with human genetic…
PR Newswire
16/10/2025

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Oct.16, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has...
Nasdaq GlobeNewswire
16/10/2025

Precision BioLogic Acquires George King Bio-Medical

Kathryn Blasco, CEO and President of George King Bio-Medical and daughter of George King, the company's founder, agrees. "Joining forces with Precision BioLogic enables us to continue our legacy of compassion and innovation. The future looks promising for us and our customers." Kathryn Blasco, CEO and President of George King Bio-Medical and daughter ofGeorge King, the company's founder, agrees. "Joining forces with Precision BioLogic enables us to continue our legacy of…
PR Newswire
16/10/2025
Altri  Comunicati